Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)

Journal of Translational Medicine

Magdalena Thurin¹  Sergio A. Quezada²  Jason J. Luke³  Pawel Kalinski⁴  Claus Garbe⁵  Reinhard Dummer⁶  Igor Puzanov⁷  Paolo A. Ascierto⁸  Thomas F. Gajewski⁹  Soldano Ferrone^1,10  Marc S. Ernstoff^1,11  Corrado Caracò^1,12  Bernard A. Fox^1,13  Alessandro Testori^1,14  Roger S. Lo^1,15  Giorgio Trinchieri^1,16  Bart Neyns^1,17  Michelle Krogsgaard^1,18  Michael A. Postow^1,19  Patrick Hwu^2,20  Christian Blank^2,21  Iman Osman^2,22  Michele W. L. Teng^2,23 

[1] Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA;Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK;Cancer Immunotherapeutic Center of UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA;Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, USA;Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany;Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland;Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Instituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy;Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA;Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, NIH, Bethesda, MD, USA;Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori “Fondazione Pascale” IRCCS, Naples, Italy;Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA;Image Rigenerative Clinic-Skin Oncology Division, Milan, Italy;Chairman Surgical Subgroup EORTC Melanoma Group Brussels, Brussels, Belgium;Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research, NCI, NIH, Bethesda, MD, USA;Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium;Medical School, New York University Langone, New York, NY, USA;Memorial Sloan Kettering Cancer Center, New York, NY, USA;Weill Cornell Medical College, New York, NY, USA;Moffitt Cancer Center, Tampa, FL, USA;Netherlands Cancer Institute, Amsterdam, The Netherlands;New York University Langone Medical Center, New York, NY, USA;QIMR Berghofer Medical Research Institute, Herston, QLD, Australia;

关键词: Melanoma;    Immunotherapy;    Anti-PD-1;    Anti-CTLA-4;    Target therapy;    Biomarkers;    BRAF inhibitor;    MEK inhibitor;    Adjuvant;    Neoadjuvant;    Combination strategies;   

DOI  :  10.1186/s12967-021-02951-x

来源: Springer

【 摘 要 】

Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK targeted therapy demonstrated benefit in overall survival (OS). Superior response rates have been demonstrated with combined PD-1/CTLA-4 blockade, with a significant OS benefit compared with single-agent PD-1 blockade. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers but they have yet to be fully characterized and implemented clinically. Overall, the progress in melanoma therapeutics and translational research will help to optimize treatment regimens to overcome resistance and develop robust biomarkers to guide clinical decision-making. During the Melanoma Bridge meeting (December 3rd–5th, 2020, Italy) we reviewed the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine.

【 授权许可】

CC BY